CRNX
Crinetics Pharmaceuticals, Inc. NASDAQ Listed Jul 18, 2018$43.48
Mkt Cap $4.6B
52w Low $25.83
54.9% of range
52w High $57.99
50d MA $38.40
200d MA $40.82
P/E (TTM)
-7.9x
EV/EBITDA
-9.4x
P/B
3.7x
Debt/Equity
0.1x
ROE
-46.9%
P/FCF
-11.4x
RSI (14)
—
ATR (14)
—
Beta
0.31
50d MA
$38.40
200d MA
$40.82
Avg Volume
1.1M
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Building No. 2 · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -1.22 | -1.23 | -0.8% | 43.49 | -1.0% | -13.8% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -1.37 | -1.29 | +5.8% | 43.74 | +3.2% | -6.0% | -7.0% | -8.3% | -9.7% | -11.1% | — |
| Nov 6, 2025 | AMC | -1.27 | -1.38 | -8.7% | 43.49 | -7.9% | -8.0% | -4.7% | -1.3% | -1.5% | -4.7% | — |
| Aug 7, 2025 | AMC | -1.13 | -1.23 | -8.8% | 27.88 | -0.5% | -3.7% | -1.8% | +2.2% | +7.9% | +6.5% | — |
| May 8, 2025 | AMC | -0.99 | -1.04 | -5.1% | 32.70 | +1.8% | -6.2% | +1.9% | -5.4% | -4.3% | -4.6% | — |
| Feb 27, 2025 | AMC | -0.92 | -0.88 | +4.3% | 33.21 | +2.2% | +7.7% | +2.8% | +2.6% | +2.2% | +2.7% | — |
| Nov 12, 2024 | AMC | -0.91 | -0.96 | -5.4% | 58.78 | +2.1% | +0.2% | +1.5% | -6.9% | -8.6% | -6.1% | — |
| Aug 8, 2024 | AMC | -0.86 | -0.94 | -9.3% | 50.74 | -4.7% | -6.1% | -2.3% | -0.8% | +1.4% | +3.5% | — |
| May 9, 2024 | AMC | -0.84 | -0.93 | -10.7% | 49.42 | +0.0% | -2.9% | -3.0% | -0.1% | +2.2% | +5.0% | — |
| Feb 28, 2024 | AMC | -0.89 | -0.90 | -1.1% | 42.76 | +5.4% | -4.3% | +7.6% | +1.8% | +0.4% | +1.8% | — |
| Nov 7, 2023 | AMC | -0.89 | -1.01 | -13.5% | 29.52 | -1.5% | -3.6% | -9.6% | -8.8% | -4.2% | -2.9% | — |
| Aug 8, 2023 | AMC | -0.85 | -0.94 | -10.6% | 17.30 | +1.0% | -3.6% | -2.9% | -4.5% | -2.7% | -3.4% | — |
| May 4, 2023 | AMC | -0.82 | -0.85 | -3.7% | 21.37 | +3.3% | +4.6% | +3.1% | +10.4% | +9.2% | +3.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Citizens | Maintains | Market Outperform → Market Outperform | — | $38.62 | $39.41 | +2.0% | -1.2% | -0.5% | +0.4% | +1.0% | +6.8% |
| Mar 2 | Citizens | Maintains | Market Outperform → Market Outperform | — | $41.10 | $40.46 | -1.6% | -1.0% | -2.4% | -3.9% | -5.4% | -7.0% |
| Jan 12 | Goldman Sachs | Upgrade | Neutral → Buy | — | $53.25 | $54.10 | +1.6% | +3.9% | +2.0% | +4.1% | +6.0% | +5.1% |
| Jan 8 | Citizens | Maintains | Market Outperform → Market Outperform | — | $53.34 | $53.30 | -0.1% | -0.2% | -0.2% | +3.8% | +1.8% | +3.9% |
| Jan 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $48.18 | $47.40 | -1.6% | -4.6% | +10.7% | +10.5% | +10.5% | +14.9% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $43.49 | $40.06 | -7.9% | -8.0% | -4.7% | -1.3% | -1.5% | -4.7% |
| Sep 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $43.51 | $43.43 | -0.2% | -4.3% | -4.4% | -4.6% | -6.1% | -4.2% |
| Sep 29 | Leerink Partners | Maintains | Outperform → Outperform | — | $45.91 | $45.91 | +0.0% | -5.2% | -9.3% | -9.4% | -9.6% | -11.0% |
| Sep 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $45.91 | $45.91 | +0.0% | -5.2% | -9.3% | -9.4% | -9.6% | -11.0% |
| Sep 26 | Goldman Sachs | Maintains | Neutral → Neutral | — | $35.89 | $41.07 | +14.4% | +27.9% | +21.2% | +16.0% | +15.9% | +15.7% |
| Sep 26 | Baird | Maintains | Outperform → Outperform | — | $35.89 | $41.07 | +14.4% | +27.9% | +21.2% | +16.0% | +15.9% | +15.7% |
| Sep 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $35.89 | $41.07 | +14.4% | +27.9% | +21.2% | +16.0% | +15.9% | +15.7% |
| Sep 24 | JP Morgan | Maintains | Overweight → Overweight | — | $35.86 | $35.34 | -1.5% | -1.9% | +0.1% | +28.0% | +21.3% | +16.1% |
| Aug 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $26.85 | $26.78 | -0.3% | +2.0% | +6.1% | +12.1% | +10.6% | +14.4% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.99 | $30.12 | +0.4% | -0.1% | -4.1% | -5.2% | -1.8% | -0.6% |
| Feb 28 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $33.21 | $33.94 | +2.2% | +7.7% | +2.8% | +2.6% | +2.2% | +2.7% |
| Jan 22 | Jefferies | Upgrade | Hold → Buy | — | $38.76 | $40.00 | +3.2% | -0.3% | +1.1% | +0.1% | -1.4% | -1.4% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.59 | $40.74 | +0.4% | -4.0% | -12.2% | -9.5% | -10.1% | -8.0% |
| Dec 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $53.66 | $53.21 | -0.8% | +1.8% | +3.2% | -2.9% | -1.7% | -0.1% |
| Nov 14 | Citigroup | Maintains | Buy → Buy | — | $58.92 | $58.28 | -1.1% | +1.3% | -7.1% | -8.9% | -6.4% | -4.8% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $58.78 | $60.00 | +2.1% | +0.2% | +1.5% | -6.9% | -8.6% | -6.1% |
| Sep 27 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $50.58 | $51.23 | +1.3% | +0.3% | +1.0% | +2.6% | +6.8% | +4.3% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $53.80 | $53.90 | +0.2% | +0.3% | -1.5% | -1.9% | +0.1% | -1.2% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.74 | $48.36 | -4.7% | -6.1% | -2.3% | -0.8% | +1.4% | +3.5% |
| Aug 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $50.74 | $48.36 | -4.7% | -6.1% | -2.3% | -0.8% | +1.4% | +3.5% |
| Jul 9 | JP Morgan | Maintains | Overweight → Overweight | — | $45.37 | $45.79 | +0.9% | +6.3% | +12.0% | +16.4% | +18.3% | +19.3% |
| Jul 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.07 | $46.09 | +0.0% | -1.2% | -4.1% | -4.9% | -1.5% | +4.7% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.47 | $43.67 | +0.5% | +3.0% | +6.0% | +4.8% | +1.7% | +0.8% |
| Jun 4 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $46.28 | $46.67 | +0.8% | +2.3% | +2.1% | -1.0% | -3.4% | -2.7% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.28 | $46.67 | +0.8% | +2.3% | +2.1% | -1.0% | -3.4% | -2.7% |
| Jun 4 | Oppenheimer | Maintains | Outperform → Outperform | — | $46.28 | $46.67 | +0.8% | +2.3% | +2.1% | -1.0% | -3.4% | -2.7% |
| May 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $50.54 | $51.52 | +1.9% | -3.8% | -6.1% | -7.3% | -9.4% | -10.2% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.54 | $51.52 | +1.9% | -3.8% | -6.1% | -7.3% | -9.4% | -10.2% |
| May 23 | Baird | Maintains | Outperform → Outperform | — | $50.54 | $51.52 | +1.9% | -3.8% | -6.1% | -7.3% | -9.4% | -10.2% |
| May 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $47.93 | $48.71 | +1.6% | +3.0% | +5.3% | +8.3% | +7.2% | +5.6% |
| May 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $49.42 | $49.43 | +0.0% | -2.9% | -3.0% | -0.1% | +2.2% | +5.0% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.42 | $49.43 | +0.0% | -2.9% | -3.0% | -0.1% | +2.2% | +5.0% |
| May 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.50 | $47.82 | +2.8% | +2.5% | +9.4% | +6.3% | +3.2% | +3.1% |
| Mar 28 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $44.43 | $44.52 | +0.2% | +5.4% | +4.7% | +3.5% | +7.2% | +5.0% |
| Mar 20 | JonesTrading | Maintains | Buy → Buy | — | $45.18 | $44.23 | -2.1% | +0.7% | -0.5% | -2.0% | -4.6% | -4.0% |
| Mar 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $45.18 | $44.23 | -2.1% | +0.7% | -0.5% | -2.0% | -4.6% | -4.0% |
| Mar 20 | Oppenheimer | Maintains | Outperform → Outperform | — | $45.18 | $44.23 | -2.1% | +0.7% | -0.5% | -2.0% | -4.6% | -4.0% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.18 | $44.23 | -2.1% | +0.7% | -0.5% | -2.0% | -4.6% | -4.0% |
| Mar 19 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $37.93 | $41.07 | +8.3% | +19.1% | +19.9% | +18.6% | +16.8% | +13.7% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.93 | $41.07 | +8.3% | +19.1% | +19.9% | +18.6% | +16.8% | +13.7% |
| Mar 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $40.75 | $41.08 | +0.8% | -0.6% | -6.2% | -4.5% | -6.9% | +10.9% |
| Mar 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $40.75 | $41.08 | +0.8% | -0.6% | -6.2% | -4.5% | -6.9% | +10.9% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.75 | $41.08 | +0.8% | -0.6% | -6.2% | -4.5% | -6.9% | +10.9% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.50 | $44.32 | +4.3% | -0.5% | -2.2% | -4.1% | -4.7% | -10.1% |
| Mar 4 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $46.03 | $47.58 | +3.4% | -5.5% | -6.7% | -5.5% | -7.7% | -8.1% |
No insider trades available.
8-K
Unknown — 8-K Filing
A key executive's departure with limited post-employment option exercise rights suggests leadership transition risk, potentially pressuring CRNX stock if the departing officer held critical operational or strategic responsibilities.
Apr 10
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis from this filing summary, as it contains only technical XBRL metadata rather than substantive business information about CRNX's operations, financial results, or strategic developments.
Mar 23
8-K · 4.01
!!! Very High
Crinetics Pharmaceuticals, Inc. -- 8-K 4.01: Auditor Change / Resignation
Crinetics Pharmaceuticals replaced its auditor from BDO to an undisclosed firm, which may signal accounting concerns or reflect routine auditor rotation and could affect investor confidence in financial reporting.
Mar 3
8-K
Crinetics Pharmaceuticals, Inc. -- 8-K Filing
Crinetics Pharmaceuticals reported full-year 2025 financial results, providing investors with updated operational performance and pipeline progress for its endocrine disease therapeutics portfolio.
Feb 26
Data updated apr 25, 2026 3:19am
· Source: massive.com